{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fu Y"],"funding":["Natural Science Foundation of Beijing Municipality","Beijing Outstanding Young Scientist Program","National Natural Science Foundation of China","Fund for Beijing Science & Technology Development of TCM","CAMS Initiative for Innovative Medicine"],"pagination":["15938"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9786790"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(24)"],"pubmed_abstract":["Voglibose is an α-glycosidase inhibitor that improves postprandial hyperglycemia and increases glucagon-like peptide-1 (GLP-1) secretion in patients with type 2 diabetes. Recently, there has been increasing interest in the anti-inflammatory effects of voglibose on the intestine, but the underlying mechanism is not clear. This study evaluated the effects and mechanisms of voglibose on glycemic control and intestinal inflammation. Type 2 diabetic KKAy mice were treated with voglibose (1 mg/kg) by oral gavage once daily. After 8 weeks, glucose metabolism, levels of short-chain fatty acids (SCFAs), systematic inflammatory factors, intestinal integrity and inflammation were evaluated using hematoxylin and eosin staining, immunohistochemistry, immunofluorescence and Western blot analysis. Voglib"],"journal":["International journal of molecular sciences"],"pubmed_title":["Voglibose Regulates the Secretion of GLP-1 Accompanied by Amelioration of Ileal Inflammatory Damage and Endoplasmic Reticulum Stress in Diabetic KKAy Mice."],"pmcid":["PMC9786790"],"funding_grant_id":["JJ-2020-25","2022-I2M-2-002","BJJWZYJH01201910023028","7202137","2021-I2M-1-026","81900480","2022-I2M-JB0011","81973379"],"pubmed_authors":["Lei L","Li C","Cao H","Chen L","Huan Y","Fu Y","Liu Q","Li P","Zhang L","Liu S","Feng C","Shen Z","Ji W","Gao X","Zhai J"],"additional_accession":[]},"is_claimable":false,"name":"Voglibose Regulates the Secretion of GLP-1 Accompanied by Amelioration of Ileal Inflammatory Damage and Endoplasmic Reticulum Stress in Diabetic KKAy Mice.","description":"Voglibose is an α-glycosidase inhibitor that improves postprandial hyperglycemia and increases glucagon-like peptide-1 (GLP-1) secretion in patients with type 2 diabetes. Recently, there has been increasing interest in the anti-inflammatory effects of voglibose on the intestine, but the underlying mechanism is not clear. This study evaluated the effects and mechanisms of voglibose on glycemic control and intestinal inflammation. Type 2 diabetic KKAy mice were treated with voglibose (1 mg/kg) by oral gavage once daily. After 8 weeks, glucose metabolism, levels of short-chain fatty acids (SCFAs), systematic inflammatory factors, intestinal integrity and inflammation were evaluated using hematoxylin and eosin staining, immunohistochemistry, immunofluorescence and Western blot analysis. Voglib","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-04-29T03:22:28.721Z","creation":"2025-04-07T02:58:21.79Z"},"accession":"S-EPMC9786790","cross_references":{"pubmed":["36555580"],"doi":["10.3390/ijms232415938"]}}